SEC F	Form 4
-------	--------

FORM	4
------	---

Check this box if no longer subject to

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response 0.5

Section 16. F	Form 4 or Form 5 lay continue. See b).		Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940	34	Estimated aver hours per resp	0	.5
1. Name and Add	dress of Reporting F Sean A.	Person*	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>CytomX Therapeutics, Inc.</u> [ CTMX ]		ible)	10% Owner Other (specify	
(Last) 343 OYSTER SUITE 100	(First) R POINT BLVD.	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 09/26/2016	below)	President and C	below) CEO	
(Street) SOUTH SAN FRANCISCO	CA	94080	4. If Amendment, Date of Original Filed (Month/Day/Year)		int/Group Filing (( ed by One Report ed by More than C	ing Person	
(City)	(State)	(Zip)					

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	Date (Month/Day/Year)	Execution Date, f any Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (Right to Buy)	\$0.945	09/26/2016		Α		48,379		(1)	02/25/2023	Common Stock	48,379	\$0.00	48,379	D	
Stock Option (Right to Buy)	\$1.5749	09/26/2016		Α		122,424		(2)	02/08/2025	Common Stock	122,424	\$0.00	122,424	D	

## Explanation of Responses:

1. On February 26, 2013, the Reporting Person was granted an option to purchase 96,758 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public performance option of the method is a second performance-based milestones (the "Performance Option"). 50% of the Performance Option previously vested upon achievement of the first performance option. On September 26, 2016, the second performance milestone was achieved resulting in vesting of the remaining 50% of the Performance Option.

2. On February 9, 2015, the Reporting Person was granted an option to purchase 122,424 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public offering, to vest in full upon achievement of a certain performance-based milestone (the "Performance Option"). On September 26, 2016, the performance milestone was achieved resulting in 100% of the Performance Option vesting.

## /s/ Cynthia J. Ladd, as Attorney-in-Fact for Sean A. McCarthy

09/28/2016

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.